Day: November 9, 2022

2′-Deoxy-2′-fluoro-β-D-arabinonucleosides and oligonucleotides (2’F-ANA): synthesis and physicochemical studies was written by Wilds, Christopher J.; Damha, Masad J.. And the article was included in Nucleic Acids Research on September 15,2000.Electric Literature of C9H12FN3O4 The following contents are mentioned in the article:

Recently, hybrids of RNA and D-arabinonucleic acids (ANA) as well as the 2′-deoxy-2′-fluoro-D-arabinonucleic acid analog (2’F-ANA) were shown to be substrates of RNase H. This enzyme is believed to be involved in the primary mechanism by which antisense oligonucleotides cause a reduction in target RNA levels in vivo. To gain a better understanding of the properties of arabinose based oligonucleotides, we have prepared a series of 2’F-ANA sequences of homopolymeric (A and T) and mixed base composition (A, T, G and C). UV thermal melting and circular dichroic (CD) studies were used to ascertain the thermodn. stability and helical conformation of 2’F-ANA/RNA and 2’F-ANA/DNA hybrids. It is shown that 2’F-ANA has enhanced RNA affinity relative to that of DNA and phosphorothioate DNA. The 2′-fluoroarabino modification showed favorable pairing to single-stranded DNA also. This is in sharp contrast to ANA, which forms weak ANA/DNA hybrids at best. According to the measured thermodn. parameters for duplex formation, the increased stability of hybrids formed by 2’F-ANA (e.g., 2’F-ANA/RNA) appears to originate from conformational pre-organization of the fluorinated sugars and a favorable enthalpy of hybridization. In addition, NMR spectroscopy revealed a five-bond coupling between the 2’F and the base protons (H6/H8) of 2′-deoxy-2′-fluoro-β-D-arabinonucleosides. This observation is suggesting of a through-space interaction between 2’F and H6/H8 atoms. CD experiments indicate that 2’F-ANA/RNA hybrids adopt an ‘A-like’ structure and show more resemblance to DNA/RNA hybrids than to the pure RNA/RNA duplex. This feature is believed to be an important factor in the mechanism that allows RNase H to discriminate between 2’F-ANA/RNA (or DNA/RNA) and RNA/RNA duplexes. This study involved multiple reactions and reactants, such as 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8Electric Literature of C9H12FN3O4).

4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8) belongs to pyrimidine derivatives. The pyrimidine derivatives can easily interact with enzymes, genetic materials, and bio components within the cell. A Cu-catalyzed and 4-HO-TEMPO-mediated [3 + 3] annulation of commercially available amidines with saturated ketones enables an efficient and facile synthesis of structurally important pyrimidines via a cascade reaction of oxidative dehydrogenation/annulation/oxidative aromatization.Electric Literature of C9H12FN3O4

56632-83-8;4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one;The future of 56632-83-8;New trend of C9H12FN3O4;function of 56632-83-8

Pharmacological disposition and metabolic fate of 2′-fluoro-5-iodo-1-β-D-arabinofuranosylcytosine in mice and rats was written by Chou, Ting-Chao; Feinberg, Aaron; Grant, Alan J.; Vidal, Pedro; Reichman, Uri; Watanabe, Kyoichi A.; Fox, Jack J.; Philips, Frederick S.. And the article was included in Cancer Research on September 30,1981.Name: 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one The following contents are mentioned in the article:

2′-Fluoro-5-iodo-1-β-D-arabinofuranosylcytosine-HCl (FIAC)(I) [69123-90-6] was synthesized and labeled with 14C in the 2 position for the study of pharmacol. disposition and metabolic fate. FIAC is deaminated by cytosine nucleoside deaminase [9025-06-3] at a rate comparable to that of 1-β-D-arabinofuranosylcytosine. The deaminated product, 2′-fluoro-5-iodo-1-β-D-arabinofuranosyluracil (FIAU) [69123-98-4] is, like FIAC, an active antiviral agent. After i.v. injection of [2-14C]-FIAC in mice, most of the radioactivity in plasma appears as FIAU. In i.v.-injected rats which lack cytosine nucleoside deaminase, plasma radioactivity is largely present in unchanged FIAC. If mice are pretreated with tetrahydrouridine, an inhibitor of the nucleoside deaminase, plasma radioactivity is mostly FIAC. The radioactivity of [2-14C]-FIAC injected i.v. is excreted in urine, at 63 to 93% of the dose in mice and >90% of the dose in rats within 0 to 24 h. Most of the radioactivity in urine of rats and in mice pretreated with tetrahydrouidine is present as unchanged FIAC; in control mice, most of the radioactivity is found as FIAU. Chromatog. anal. of urine from control mice receiving labeled FIAC has revealed that radioactivity is present in the following nucleosides: FIAC (14.5); FIAU (73); 2′-fluoro-5-methyl-1-β-D-arabinofuranosyluracil (FMAU) [69256-17-3] (5.4); and 2′-fluoro-1-β-D-arabinofuranosyluracil [69123-94-0] (2.3%). These metabolites are also present in acid-soluble fractions of mouse blood, small intestine, and liver. Like FIAC and FIAU, FMAU is a potent antiherpetic agent. Only âˆ?.3% of the radioactivity of injected [2-14C]-FIAC appears in mouse respiratory CO2; degradation to CO2 can be blocked by tetrahydrouridine. Less than 2% of the total radioactivity is excreted in bile in rats. Small amounts of radioactivity are also recovered in feces, mostly in deaminated products. FIAC and FIAU, with a 2′-F substituent in the arabino configuration, are less susceptible to metabolic glycosyl cleavage than is 5-iodo-2′-deoxyuridine. The radioactivity of [2-14C]-FIAC is incorporated into DNA fractions of highly proliferating organs such as intestine, spleen, and thymus, although preliminary results indicate that the substances incorporated are arabinofuranosyl nucleoside metabolites of FIAC. This study involved multiple reactions and reactants, such as 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8Name: 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one).

4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8) belongs to pyrimidine derivatives. The aromatic compound pyrimidine, and its derivatives, are ubiquitous in nature. They are found in nucleic acids, vitamins, amino acids, antibiotics, alkaloids, and a variety of toxins. Therapy for fungal infections is based mainly on four classes of antifungals: azoles, echinocandins, polyenes, and pyrimidine analogs.Name: 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

56632-83-8;4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one;The future of 56632-83-8;New trend of C9H12FN3O4;function of 56632-83-8

Pharmacological disposition and metabolic fate of 2′-fluoro-5-iodo-1-β-D-arabinofuranosylcytosine in mice and rats was written by Chou, Ting-Chao; Feinberg, Aaron; Grant, Alan J.; Vidal, Pedro; Reichman, Uri; Watanabe, Kyoichi A.; Fox, Jack J.; Philips, Frederick S.. And the article was included in Cancer Research on September 30,1981.Quality Control of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione The following contents are mentioned in the article:

2′-Fluoro-5-iodo-1-β-D-arabinofuranosylcytosine-HCl (FIAC)(I) [69123-90-6] was synthesized and labeled with 14C in the 2 position for the study of pharmacol. disposition and metabolic fate. FIAC is deaminated by cytosine nucleoside deaminase [9025-06-3] at a rate comparable to that of 1-β-D-arabinofuranosylcytosine. The deaminated product, 2′-fluoro-5-iodo-1-β-D-arabinofuranosyluracil (FIAU) [69123-98-4] is, like FIAC, an active antiviral agent. After i.v. injection of [2-14C]-FIAC in mice, most of the radioactivity in plasma appears as FIAU. In i.v.-injected rats which lack cytosine nucleoside deaminase, plasma radioactivity is largely present in unchanged FIAC. If mice are pretreated with tetrahydrouridine, an inhibitor of the nucleoside deaminase, plasma radioactivity is mostly FIAC. The radioactivity of [2-14C]-FIAC injected i.v. is excreted in urine, at 63 to 93% of the dose in mice and >90% of the dose in rats within 0 to 24 h. Most of the radioactivity in urine of rats and in mice pretreated with tetrahydrouidine is present as unchanged FIAC; in control mice, most of the radioactivity is found as FIAU. Chromatog. anal. of urine from control mice receiving labeled FIAC has revealed that radioactivity is present in the following nucleosides: FIAC (14.5); FIAU (73); 2′-fluoro-5-methyl-1-β-D-arabinofuranosyluracil (FMAU) [69256-17-3] (5.4); and 2′-fluoro-1-β-D-arabinofuranosyluracil [69123-94-0] (2.3%). These metabolites are also present in acid-soluble fractions of mouse blood, small intestine, and liver. Like FIAC and FIAU, FMAU is a potent antiherpetic agent. Only âˆ?.3% of the radioactivity of injected [2-14C]-FIAC appears in mouse respiratory CO2; degradation to CO2 can be blocked by tetrahydrouridine. Less than 2% of the total radioactivity is excreted in bile in rats. Small amounts of radioactivity are also recovered in feces, mostly in deaminated products. FIAC and FIAU, with a 2′-F substituent in the arabino configuration, are less susceptible to metabolic glycosyl cleavage than is 5-iodo-2′-deoxyuridine. The radioactivity of [2-14C]-FIAC is incorporated into DNA fractions of highly proliferating organs such as intestine, spleen, and thymus, although preliminary results indicate that the substances incorporated are arabinofuranosyl nucleoside metabolites of FIAC. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Quality Control of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The pyrimidine ring system has wide occurrence in nature as substituted and ring fused compounds and derivatives. We all know its importance to life – pyrimidine and purine bases are included in the structure of DNA and RNA.Quality Control of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Rapid Enantiomeric Quantification of an Antiviral Nucleoside Agent (D,L-FMAU, 2′-Fluoro-5-methyl-β,D,L-arabinofurano- syluracil) by Mass Spectrometry was written by Tao, W. Andy; Wu, Lianming; Cooks, R. Graham; Wang, Feng; Begley, John A.; Lampert, Bernhard. And the article was included in Journal of Medicinal Chemistry on October 25,2001.HPLC of Formula: 69256-17-3 The following contents are mentioned in the article:

A novel mass spectrometric method was applied to rapid, accurate (<1%) quantification of chiral Clevudine (L-FMAU, 2'-fluoro-5-methyl-β,L-arabinofuranosyluracil), a potent antiviral nucleoside agent against hepatitis B virus. Transition metal bound complex ions containing the chiral drug are generated by electrospray ionization mass spectrometry and subjected to collision-induced dissociation The ratio of the two competitive dissociation rates is related to the enantiomeric composition of the drug mixture, allowing the determination of enantiomeric contamination in the drug. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3HPLC of Formula: 69256-17-3).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The aromatic compound pyrimidine, and its derivatives, are ubiquitous in nature. They are found in nucleic acids, vitamins, amino acids, antibiotics, alkaloids, and a variety of toxins. Therapy for fungal infections is based mainly on four classes of antifungals: azoles, echinocandins, polyenes, and pyrimidine analogs.HPLC of Formula: 69256-17-3

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Accurately Modeling the Conformational Preferences of Nucleosides was written by Burai Patrascu, Mihai; Malek-Adamian, Elise; Damha, Masad J.; Moitessier, Nicolas. And the article was included in Journal of the American Chemical Society on October 4,2017.Safety of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione The following contents are mentioned in the article:

Sugar puckering of nucleosides impacts nucleic acid structures; hence their biol. function. Similarly, nucleoside-based therapeutics may adopt different conformations affecting their binding affinity, DNA incorporation, and excision rates. As a result, significant efforts have been made to develop nucleoside analogs adopting specific conformations to improve bioactivity and pharmacokinetic profiles of the corresponding nucleoside-containing drugs. Understanding and ultimately predicting these conformational preferences would significantly help in the design of more effective structures. The authors report herein a computational study based on hybrid QM/MM umbrella sampling simulations that allow the accurate prediction of the sugar conformational preferences of chem. modified nucleosides in solution Moreover, the authors pair these simulations with natural bond orbital (NBO) anal. to gain key insights into the role of substituents in the conformational preferences of these nucleosides. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Safety of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The pyrimidine ring system has wide occurrence in nature as substituted and ring fused compounds and derivatives. Drugs having the pyrimidine motif have manifested to exhibit gratifying biological activity like anticancer, antiviral, anti-inflammatory, antibacterial, and antihypertensive activities.Safety of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Comparative anti-herpesvirus activities of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, acyclovir, and two 2′-fluoropyrimidine nucleosides was written by Smee, Donald F.; Campbell, Nancy L.; Matthews, Thomas R.. And the article was included in Antiviral Research on October 31,1985.HPLC of Formula: 69256-17-3 The following contents are mentioned in the article:

9-(1,3-Dihydroxy-2-propoxymethyl)guanine (DHPG) [82410-32-0], was evaluated in cell culture and in animals for its inhibitory effect on herpes simplex viruses. Compounds used for comparison included acyclovir  [59277-89-3], 2′-fluoro-2′-deoxy-5-iodoarabinofuranosylcytosine (FIAC) [69123-90-6], and 2′-fluoro-2′-deoxy-5-methylarabinofuranosyluracil (FMAU) [69256-17-3]. In plaque-reduction assays DHPG, acyclovir, FIAC, and FMAU were inhibitory to 6 herpes types 1 and 2 virus strains at concentrations of 0.2-2.4 μM. These concentrations were much lower than those required to inhibit Vero cell proliferation. In guinea pig vaginal infections, DHPG provided significantly greater inhibition of herpetic lesions than did acyclovir. In a herpes type 2 infection model in mice, DHPG, and FMAU were active at 5 mg/kg, whereas acyclovir and FIAC showed no statistically significant effect at 80 mg/kg. In a herpes type 1 encephalitis model, DHPG and FMAU were active at doses <10 mg/kg, with FMAU being about 4 times more potent than DHPG in that model. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3HPLC of Formula: 69256-17-3).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. Heterocyclic compounds bearing the pyrimidine core are of tremendous interest as they constitute an important class of natural and synthetic compounds exhibiting diverse useful biological activities that hold attractive potential for clinical translation as therapeutic agents in alleviation of a myriad of diseases. A Cu-catalyzed and 4-HO-TEMPO-mediated [3 + 3] annulation of commercially available amidines with saturated ketones enables an efficient and facile synthesis of structurally important pyrimidines via a cascade reaction of oxidative dehydrogenation/annulation/oxidative aromatization.HPLC of Formula: 69256-17-3

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Cell-specific antiviral activity of 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-5-iodocytosine (FIAC) against Marek’s disease herpesvirus and turkey herpesvirus was written by Schat, Karel A.; Schinazi, Raymond F.; Calnek, Bruce W.. And the article was included in Antiviral Research on October 31,1984.Related Products of 69256-17-3 The following contents are mentioned in the article:

Three new fluoroarabinosylpyrimidine nucleosides [1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl-5-iodocytosine (FIAC)(I) [69123-90-6], 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-5-iodouracil (FIAU)(II) [69123-98-4], and 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-5-methyluracil (FMAU)(III) [69256-17-3]] were tested for in vitro activity against oncogenic and nononcogenic strains of Marek’s disease virus (MDV) and herpesvirus of turkeys (HVT). Marek’s disease is a herpesvirus-induced lymphoma in chickens. Nononcogenic strains of MDV and HVT can protect against this disease. All viruses were inhibited by 1 μM of these drugs in chick kidney cell (CKC) cultures, but only FMAU and FIAU were active in chicken embryo fibroblast (CEF) and spleen cell cultures. It was determined that whereas CKC produced the enzyme 2′-deoxycytidine-deaminase  [37259-56-6] which is needed to deaminate FIAC to FIAU, CEF were devoid of this enzyme activity. In addition, the deaminase inhibitor 3,4,5,6-tetrahydrouridine prevented the antiviral activity of FIAC and CKC. FMAU was not active against two Marek’s disease-derived lymphoblastoid tumor cell lines. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Related Products of 69256-17-3).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. Pyrimidines are isomeric with two other forms of diazines: pyridazine, with the nitrogen atoms in the 1 and 2 positions; and pyrazine, with the nitrogen atoms in the 1 and 4 positions. Pyrimidine derivatives also play an important role in drug development, either in concert with other compounds or on their own.Related Products of 69256-17-3

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Efficacy and selectivity of some nucleoside analogs as antihuman cytomegalovirus agents was written by Colacino, Joseph M.; Lopez, Carlos. And the article was included in Antimicrobial Agents and Chemotherapy on October 31,1983.Name: 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione The following contents are mentioned in the article:

1-(2′-Deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-iodocytosine (FIAC) [69123-90-6], 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-methyluridine (FMAU) [69256-17-3], 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-iodouridine (FIAU) [69123-98-4], and 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-ethyluridine (FEAU) [83546-42-3] were evaluated for antiviral activities against human cytomegalovirus (HCMV) and compared with 9-[(2-hydroxyethoxy)methyl]guanine (acylovir) [59277-89-3] and E-5-(2′-bromovinyl)-2′-deoxyuridine (BVDU) [69304-47-8]. The relative anti-HCMV potencies of these compounds, as determined by calculating the dose of drug which inhibited 50% plaque formation, were in order of decreasing potency: FIAC > FIAU > FMAU > acyclovir > FEAU > BVDU. The antiviral activity of FIAC occurred at levels much lower than those that caused cytotoxic or cytostatic effects in uninfected fibroblasts. Neither thymidine nor deoxycytidine reversed the anti-HCMV activity of FIAC, indicating that this drug was not acting as an analog of the natural nucleosides. FIAC was not phosphorylated by cytosols of HCMV-infected cells to a greater extent that by those of uninfected cells, indicating that, unlike the antiviral activity against herpes simplex virus type 1, the selectivity of this drug is probably not based on a virus-specified pyrimidine kinase. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Name: 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The pyrimidine nitrogenous bases are derived from the organic compound pyrimidine through the addition of various functional groups. A Cu-catalyzed and 4-HO-TEMPO-mediated [3 + 3] annulation of commercially available amidines with saturated ketones enables an efficient and facile synthesis of structurally important pyrimidines via a cascade reaction of oxidative dehydrogenation/annulation/oxidative aromatization.Name: 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

An Escherichia coli system expressing human deoxyribonucleoside salvage enzymes for evaluation of potential antiproliferative nucleoside analogs was written by Wang, Jianghai; Neuhard, Jan; Eriksson, Staffan. And the article was included in Antimicrobial Agents and Chemotherapy on October 31,1998.Product Details of 69256-17-3 The following contents are mentioned in the article:

Deoxyribonucleoside salvage in animal cells is mainly dependent on two cytosolic enzymes, thymidine kinase (TK1) and deoxycytidine kinase (dCK), while Escherichia coli expresses only one type of deoxynucleoside kinase, i.e., TK. A bacterial whole-cell system based on genetically modified E. coli was developed in which the relevant bacterial deoxypyrimidine metabolic enzymes were mutated, and the cDNA for human dCK or TK1 under the control of the lac promoter was introduced. The TK level in extract from induced bacteria with cDNA for human TK1 was found to be 20,000-fold higher than that in the parental strain, and for the strain with human dCK, the enzyme activity was 160-fold higher. The in vivo incorporation of deoxythymidine (Thd) and deoxycytidine (dCyd) into bacterial DNA by the two recombinant strains was 20 and 40 times higher, resp., than that of the parental cells. A number of nucleoside analogs, including cytosine arabinoside, 5-fluoro-dCyd, difluoro-dCyd, and several 5-halogenated deoxyuridine analogs, were tested with the bacterial system, as well as with human T-lymphoblast CEM cells. The results showed a close correlation between the inhibitory effects of several important cytostatic and antiviral analogs on the recombinant bacteria and the cellular system. Thus, E. coli expressing human salvage kinases is a rapid and convenient model system which may complement other screening methods in drug discovery projects. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Product Details of 69256-17-3).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The aromatic compound pyrimidine, and its derivatives, are ubiquitous in nature. They are found in nucleic acids, vitamins, amino acids, antibiotics, alkaloids, and a variety of toxins. A Cu-catalyzed and 4-HO-TEMPO-mediated [3 + 3] annulation of commercially available amidines with saturated ketones enables an efficient and facile synthesis of structurally important pyrimidines via a cascade reaction of oxidative dehydrogenation/annulation/oxidative aromatization.Product Details of 69256-17-3

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Biochemical effects of 2′-fluoro-5-methyl-1-β-D-arabinofuranosyluracil and 2′-fluoro-5-iodo-1-β-D-arabinofuranosylcytosine in mouse leukemic cells sensitive and resistant to 1-β-D-arabinofuranosylcytosine was written by Chou, Ting Chao; Burchenal, Joseph H.; Schmid, Franz A.; Braun, Thomas J.; Su, Tsann Long; Watanabe, Kyoichi A.; Fox, Jack J.; Philips, Frederick S.. And the article was included in Cancer Research on October 31,1982.Recommanded Product: 69256-17-3 The following contents are mentioned in the article:

2′-fluoro-5-methyl-1-β-D-arabinofuranosyluracil (FMAU)(I) [69256-17-3], like 2′-fluoro-5-iodo-1-β-D-arabinofuranosylcytosine (FIAC)(II) [69123-90-6], has potent antiviral activity, but unlike FIAC, it also has antileukemic effects. The 2 agents and 1-β-D-arabinofuranosylcytosine (ara-C) [147-94-4] are compared herein. Concentrations inhibiting thymidine (dThd) incorporation into DNA by 50% are for FMAU, FIAC, and ara-C, resp., in L1210/0, 32, 353, and 0.2 μm and in L1210/ara-C, 17, <10,000, and 3900 μM. Other FMAU analogs, 2'-fluoro-5-ethyl-1-β-D-arabinofuranosyluracil  [69123-98-4], inhibit dThd incorporation equally in ara-C-sensitive and -resistant cells; however, their potencies are weaker than that of FMAU. Similar results are obtained when [3H]deoxyadenosine is used as a precursor of incorporation. In L1210/0 cells, incorporation of [2-14C]FMAU radioactivity into DNA is completely inhibited by dThd and deoxycytidine (dCyd), whereas the incorporation of [2-14C]FIAC radioactivity is competitively inhibited by dCyd but not appreciably by dThd. In L1210/0 cells, FMAU has little inhibitory effect on the tritium release from [5-3H]deoxyuridine but markedly inhibits the incorporation of [2-14C]deoxyuridine into DNA. FIAC, by contrast, predominately inhibits the release of tritium from [5-3H]deoxyuridine but has little effect on subsequent incorporation into DNA. Apparently, (1) FIAC, but not FMAU, is cross-resistant to ara-C; (2) FMAU is particularly effective against L1210/ara-C cells; (3) FIAC behaves metabolically like dCyd, and FMAU like dThd and dCyd; (4) dCyd and dThd may be used as chemotherapeutic modulators; and (5) FIAC predominately inhibits dThd kinase and(or) thymidine monophosphate synthetase, whereas FMAU predominately inhibits DNA polymerase and(or) nucleotide kinases. Similar conclusions were obtained when P815/0 and P815/ara-C cells were used. The relative potencies of FIAC and FMAU in inhibiting dThd incorporation into DNA in leukemic sublines correlate with cytotoxicity in vitro and chemotherapeutic effects in vivo. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Recommanded Product: 69256-17-3).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. Heterocyclic compounds bearing the pyrimidine core are of tremendous interest as they constitute an important class of natural and synthetic compounds exhibiting diverse useful biological activities that hold attractive potential for clinical translation as therapeutic agents in alleviation of a myriad of diseases. Pyrimidine derivatives have been used in a wide variety of pharmaceuticals including general anesthetics, anti-epilepsy medication, anti-malaria medication, drugs for treating high blood pressure, and HIV medication.Recommanded Product: 69256-17-3

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3